BIOTIME INC Form 8-K August 26, 2010 SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 26, 2010

BioTime, Inc. (Exact name of registrant as specified in its charter)

California1-1283094-3127919(State or other jurisdiction of(Commission File Number)(IRS Employer)

incorporation)

Identification No.)

1301 Harbor Bay Parkway Alameda, California 94502 (Address of principal executive offices)

(510) 521-3390 (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: BIOTIME INC - Form 8-K

Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's other reports filed with the Securities and Exchange Commission. Words such as "expects," "may," "will," "anticipates," "intends," "plans," "believes, "estimates," and similar expressions identify forward-looking statements.

Section 8 – Other Events

Item 8.01 – Other Events.

On September 1, 2010 we will be offering for sale seven new human embryonic progenitor cell lines for research use only. The new progenitor lines were produced from embryonic stem cells using our ACTCellerateTM technology. The seven new cell lines have markers of diverse mesoderm and neural crest cell types and are designated W11, Z2, SK31, SM35, T36, EN51, and EN55.

Human embryonic progenitor cells are intermediate in the developmental process between embryonic stem cells and fully differentiated cells. The cells may possess the ability to become a wide array of cell types with potential applications in research, drug discovery, and potential novel regenerative stem cell therapies. The cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of human embryonic stem cells.

In addition to offering these new progenitor cell lines, we will also simultaneously launch corresponding cell culture media and differentiation kits. Information about the products will be available online at www.embryome.com/products.htm beginning September 1, 2010.

Section 9 - Financial Statements and Exhibits

Item 9.01 – Financial Statements and Exhibits.

Exhibit NumberDescription99.1Press release dated August 26, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOTIME, INC.

Date:	August 26, 2010	By:	/s/ Steven A. Seinberg
			Chief Financial Officer

Exhibit NumberDescription99.1Press release dated August 26, 2010

ont>

(Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

0	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
0	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
0	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
0	Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

2008 Earnings

On February 6, 2009, PNM Resources, Inc. ("PNMR" or the "Company") announced unaudited preliminary 2008 Generally Accepted Accounting Principles ("GAAP") and on-going earnings (losses) and reported that it was in the process of determining whether additional impairment charges related to goodwill for First Choice Power would be recorded. The Company completed its impairment analysis and recorded a \$39.4 million goodwill impairment charge to GAAP losses for the quarter and year ended December 31, 2008. In addition, the preliminary earnings information was subject to the year-end audit by the Company's auditors and subject to final review and adjustment by the Company. The Company has completed its review and as a result made an additional adjustment to its previously reported preliminary results of operations for the quarter and year that resulted in an after-tax reduction of \$1.7 million to GAAP and on-going earnings (losses). This additional reduction is related to bad debt expense at First Choice Power primarily due to the current economic conditions in the Texas market and the impact of Hurricane Ike. The above adjustments for PNMR have no effect on the financial statements of Public Service Company of New Mexico or Texas-New Mexico Power Company.

The impacts of these adjustments on quarterly and annual GAAP losses and on-going earnings (losses) per diluted share, rounded to the nearest cent, are reflected below:

Unaudited Preliminary Results	Year Ended December 31, 2008		Quarter Ended December 31, 2008	
On-going earnings (losses) per diluted share	\$	0.12	\$	(0.12)
GAAP (losses) per diluted share	\$	(2.75)	\$	(0.36)
Final Results				
On-going earnings (losses) per diluted share	\$	0.10	\$	(0.14)
GAAP (losses) per diluted share	\$	(3.24)	\$	(0.82)

The Company provided quarterly and annual reconciliations of GAAP to non-GAAP earnings and earnings per diluted share by segment in its February 6, 2009 announcement and has included updated reconciliations in the attached Schedules 1 through 4.

Non-GAAP Financial Measures

This report and other communications from the Company from time to time may include certain non- GAAP financial measures. A "non-GAAP financial measure" is defined as a numerical measure of a company's financial performance, financial position or cash flows that excludes (or includes) amounts that are included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in the Company's financial statements.

Non-GAAP financial measures utilized by the Company include presentations of revenues, operating expenses, operating income, other income and deductions, net earnings (loss), earnings (loss) per share, and earnings before interest, taxes, depreciation and amortization ("EBITDA"). The Company uses ongoing earnings (loss), ongoing earnings (loss) per diluted share (or ongoing diluted earnings (loss) per share), ongoing EBITDA, and EBITDA to evaluate the operations of the Company and to establish goals for management and employees. Certain non-GAAP

Edgar Filing: BIOTIME INC - Form 8-K

financial measures utilized by the Company exclude the impact of non-recurring items, net unrealized mark-to-market gains and losses on economic hedges, impairments of intangible assets, unrealized impairments on assets held in trusts for nuclear decommissioning, and the results of speculative trading. The Company's management believes that these non-GAAP financial measures provide useful information to investors by removing the effect of variances in GAAP reported results of operations that are not indicative of fundamental changes in the earnings capacity of the Company's operations. Management also believes that the presentation of the non-GAAP financial measures is largely consistent with its past practice, as well as industry practice in general, and will enable investors and analysts to compare current non-GAAP measures with non-GAAP measures with respect to prior periods.

The non-GAAP financial measures used by the Company should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.

Limitation on Incorporation by Reference

In accordance with general instruction B.2 of Form 8-K, the information in this report, including exhibits, is furnished pursuant to Item 2.02 and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section and not deemed incorporated by reference in any filing under the Securities Act of 1933.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PNM RESOURCES, INC.

(Registrant)

Date: March 2, 2009

/s/ Thomas G. Sategna Thomas G. Sategna Vice President and Corporate Controller (Officer duly authorized to sign this report)

PNM Resources Schedule 1: 4th Quarter 2008 Reconciliation of Ongoing Earnings to GAAP Earnings (\$ in thousands)

	PNM Electric	Electric Ga		Choice En	50%)	ther	PNMR
Ongoing Earnings (Loss)	\$ (3,700)	\$ 5,581 \$	6,951 \$	\$ (9,935) \$	(5,508) \$	(5,871)	\$ (12,482)
Non-Recurring Items							
Acquisition/Divestiture	(686)	-	(4)	-	-	(748)	(1,438)
Business improvement plan	(358)	62	(169)	-	-	(2,092)	(2,557)
Economic mark-to-market	(455)	-	(72)	(1,690)	5,148	-	2,931
hedges							
Depreciation on gas assets	-	-	3,299	-	-	-	3,299
Impairment of intangible	-	-	-	(64,248)	-	-	(64,248)
assets							
Speculative trading	-	-	-	(680)	0	-	(680)
Texas deferred tax	-	2,494	-	-	-	3,000	5,494
adjustments							
Unrealized impairments of	(3,356)	-	-	-	-	-	(3,356)
NDT securities							
Total Non-Recurring Items	(4,855)	2,556	3,054	(66,618)	5,148	160	(60,555)
GAAP Earnings (Loss) from	(8,555)	8,137		(76,553)	(360)	(5,711)	(83,042)
Continuing Operations							
GAAP Earnings (Loss) from			10,005				10,005
Discontinued Operations							
GAAP Net Earnings (Loss)	\$ (8,555)	\$ 8,137 \$	5 10,005 \$	\$ (76,553) \$	(360) \$	(5,711)	\$ (73,037)

PNM Resources Schedule 2: 2008 Reconciliation of Ongoing to GAAP Earnings (\$ in thousands)

	PNM Electric			First Optim Choice Energy (50%)		Corp/ Other	PNMR	
Ongoing Earnings (Loss)				\$ (23,795)	\$ (2,531)	\$ (26,360)	\$ 8,166	
Non-Recurring Items								
Acquisition/Divestiture	(2,170)	-	(13)	-	-	(4,096)	(6,279)	
Afton writedown	(1,199)	-	-	-	-	-	(1,199)	
Business improvement plan	(165)	(84)	(312)	-	-	(6,526)	(7,087)	
Depreciation on gas assets	-	-	13,004	-	-	-	13,004	
Economic mark-to-market	(3,471)	-	(1)	(2,136)	1,901	-	(3,707)	
hedges								
FIN 48 interest	(1,922)	29	6	66	-	12	(1,809)	
Gain on sale of merchant	3,083	-	-	-	-	-	3,083	
portfolio								
Impairment of intangible	(51,143)	(34,456)	-	(119,577)	(6,978)	-	(212,154)	
assets								
Regulatory disallowances	(18,273)	-	-	-	-	-	(18,273)	
Speculative trading	-	-	-	(32,131)	(739)	-	(32,870)	
Texas deferred tax	-	2,494	-	-	-	3,000	5,494	
adjustments								
Unrealized impairments of	(7,426)	-	-	-	-	-	(7,426)	
NDT securities								
Write-off of emissions	-	-	-	-	(9,587)	-	(9,587)	
allowances								
Total Non-Recurring Items	(82,686)	(32,017)	12,684	(153,778)	(15,403)	(7,610)	(278,810)	
GAAP Earnings (Loss) from	(67,002)	(8,793)		(177,573)	(17,934)	(33,970)	(305,272)	
Continuing Operations	(07,002)	(0,75)		(177,575)	(17,754)	(33,770)	(303,272)	
GAAP Earnings (Loss) from			34,628				34,628	
Discontinued Operations			2 .,020				2 1,020	
GAAP Net Earnings (Loss)	\$ (67.002)	\$ (8,793)	\$ 34.628	\$(177,573)	\$ (17,934)	\$ (33,970)	\$(270,644)	
2 = = = 1 (c 2 ug (2000)	÷ (0,,00 2)	+ (0,0)	÷ c .,c 2 0	+(1,1,0,0)	+ (-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	+ (22,27.0)	+(=, 0, 0 . 1)	

PNM Resources Schedule 3: 4th Quarter 2008 Reconciliation of Ongoing to GAAP Earnings per Share

			ilities NMP PN	IM Gas	Choice En		orp/ ther	PNMR
Ongoing Earnings (Loss)		\$ (0.04) \$			\$ (0.11) \$	· /	(0.07)	\$(0.14)
Non-Recurring Items								
Acquisition/Divestiture		(0.01)	-	0.00	-	-	(0.01)	(0.02)
Business improvement plan		0.00	0.00	0.00	-	-	(0.02)	(0.02)
Economic mark-to-market		(0.01)	-	0.00	(0.02)	0.06	-	0.03
hedges								
Depreciation on gas assets		-	-	0.04	-	-	-	0.04
Impairment of intangible		-	-	-	(0.72)	-	-	(0.72)
assets								
Speculative trading		-	-	-	(0.01)	0.00	-	(0.01)
Texas deferred tax		-	0.03	-	-	-	0.03	0.06
adjustments								
Unrealized impairments of		(0.04)	-	-	-	-	-	(0.04)
NDT securities								
Total Non-Recurring Items		(0.06)	0.03	0.04	(0.75)	0.06	0.00	(0.68)
GAAP Earnings (Loss) from		(0.10)	0.09		(0.86)	0.00	(0.07)	(0.94)
Continuing Operations								
GAAP Earnings (Loss) from				0.12				0.12
Discontinued Operations								
GAAP Net Earnings (Loss)		\$ (0.10) \$	0.09 \$	0.12	\$ (0.86) \$	§ 0.00 \$	(0.07)	\$(0.82)
Average Shares Outstanding (Basic and Diluted):	88,823,719							

PNM Resources Schedule 4: 2008 Reconciliation of Ongoing to GAAP Earnings per Share

		PNM	Utilities TNMP PN Electric Gas		First C Choice Ene (50	ergy (orp/ Dther	PNMR
Ongoing Earnings (Loss)			\$ 0.28 \$		\$ (0.28) \$	· ·	(0.32)	\$ 0.10
Non-Recurring Items								
Acquisition/Divestiture		(0.03)	-	0.00	-	-	(0.04)	(0.07)
Afton writedown		(0.02)		-	-	-	-	(0.02)
Business improvement plan		0.00	0.00	0.00	-	-	(0.07)	(0.07)
Depreciation on gas assets		-	-	0.16	-	-	-	0.16
Economic mark-to-market		(0.04)	-	0.00	(0.03)	0.02	-	(0.05)
hedges								
FIN 48 interest		(0.03)	0.00	0.00	0.00	-	0.00	(0.03)
Gain on sale of merchant		0.03	-	-	-	-	-	0.03
portfolio								
Impairment of intangible		(0.61)	(0.42)	-	(1.43)	(0.08)	-	(2.54)
assets								
Regulatory disallowances		(0.22)	-	-	-	-	-	(0.22)
Speculative trading		-	-	-	(0.39)	(0.01)	-	(0.40)
Texas deferred tax		-	0.03	-	-	-	0.04	0.07
adjustments								
Unrealized impairments of		(0.09)	-	-	-	-	-	(0.09)
NDT securities								
Write-off of emissions		-	-	-	-	(0.11)	-	(0.11)
allowances								
Total Non-Recurring Items		(1.01)	(0.39)	0.16	(1.85)	(0.18)	(0.07)	(3.34)
GAAP Earnings (Loss) from		(0.82)	(0.11)		(2.13)	(0.21)	(0.39)	(3.66)
Continuing Operations								
GAAP Earnings (Loss) from				0.42				0.42
Discontinued Operations GAAP Net Earnings (Loss) Average Shares Outstanding (Basic and Diluted):	83,467,701	\$ (0.82)	\$ (0.11) \$	0.42	\$ (2.13) \$	(0.21) \$	(0.39)	\$(3.24)